Comparative Pharmacology
Head-to-head clinical analysis: ARZERRA versus SOLIRIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARZERRA versus SOLIRIS.
ARZERRA vs SOLIRIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (aHUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.
None Documented
None Documented
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Terminal elimination half-life: approximately 11.3 ± 3.4 days (range 8–18 days) following biweekly dosing. This supports a dosing interval of every 2 weeks for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
Eculizumab is not metabolized by cytochrome P450 enzymes; it is degraded via general protein catabolism. Clearance is primarily through the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). No biliary or fecal excretion data are available in humans.
Category C
Category C
Antineoplastic, Monoclonal Antibody
Monoclonal Antibody